JP2020521784A5 - - Google Patents

Download PDF

Info

Publication number
JP2020521784A5
JP2020521784A5 JP2019565921A JP2019565921A JP2020521784A5 JP 2020521784 A5 JP2020521784 A5 JP 2020521784A5 JP 2019565921 A JP2019565921 A JP 2019565921A JP 2019565921 A JP2019565921 A JP 2019565921A JP 2020521784 A5 JP2020521784 A5 JP 2020521784A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
group
orn
functional variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019565921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521784A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/064355 external-priority patent/WO2018220123A1/en
Publication of JP2020521784A publication Critical patent/JP2020521784A/ja
Publication of JP2020521784A5 publication Critical patent/JP2020521784A5/ja
Pending legal-status Critical Current

Links

JP2019565921A 2017-05-31 2018-05-31 長時間作用性ｇｉｐペプチド類似体 Pending JP2020521784A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17173628 2017-05-31
EP17173628.3 2017-05-31
PCT/EP2018/064355 WO2018220123A1 (en) 2017-05-31 2018-05-31 Long-acting gip peptide analogues

Publications (2)

Publication Number Publication Date
JP2020521784A JP2020521784A (ja) 2020-07-27
JP2020521784A5 true JP2020521784A5 (enExample) 2021-07-26

Family

ID=59021262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019565921A Pending JP2020521784A (ja) 2017-05-31 2018-05-31 長時間作用性ｇｉｐペプチド類似体

Country Status (10)

Country Link
US (1) US11572399B2 (enExample)
EP (2) EP3630806B1 (enExample)
JP (1) JP2020521784A (enExample)
KR (1) KR102743887B1 (enExample)
CN (1) CN110691788B (enExample)
AU (1) AU2018276434B2 (enExample)
BR (1) BR112019025195A8 (enExample)
ES (1) ES2972848T3 (enExample)
PL (1) PL3630806T3 (enExample)
WO (1) WO2018220123A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3189072B1 (en) 2014-09-05 2018-07-18 University of Copenhagen Gip peptide analogues
BR112019025195A8 (pt) 2017-05-31 2020-07-07 Univ Copenhagen análogos do peptídeo gip de ação prolongada
TWI707865B (zh) * 2018-05-04 2020-10-21 丹麥商諾佛 儂迪克股份有限公司 Gip衍生物及其用途
US12297250B2 (en) * 2018-12-03 2025-05-13 Antag Therapeutics Aps Modified GIP peptide analogues
JP7788376B2 (ja) * 2019-12-03 2025-12-18 アンタグ セラピューティクス エーピーエス 最適化されたｇｉｐペプチド類縁体
WO2023139106A2 (en) 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
JP3270761B2 (ja) 1998-01-30 2002-04-02 ノボ ノルディスク アクティーゼルスカブ 注射器
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
ATE269103T1 (de) 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
CN1495198A (zh) 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
GB0404124D0 (en) * 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US6921748B1 (en) 1999-03-29 2005-07-26 Uutech Limited Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1853627A2 (en) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
BRPI0917580A2 (pt) 2008-08-07 2016-10-11 Ipsen Pharma Sas composto, composição farmacêutica, métodos para elicitar um efeito agonista e antagonista de um receptor de gip, para tratar condições ou doenças mediadas por ligação de receptor de gip, para tratar diabetes, para tratar distúrbios relacionados com diabete, para tratar ou previnir causas secundárias de diabete para tratar obesidade, e para estimular secreção de insulina, e, uso de um análogo de peptídeo
CA2733005C (en) 2008-08-07 2016-09-27 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
EP2328922A4 (en) 2008-08-07 2013-01-02 Ipsen Pharma Sas ANALOGUE OF GLUCOSE-DEPENDING INSULINOTROPIC POLYPEPTIDE
KR20130133104A (ko) 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
RU2012136450A (ru) * 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
SG191252A1 (en) 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
WO2012167744A1 (en) * 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
US20140377171A1 (en) * 2011-06-10 2014-12-25 Jean Claude Reubi Imaging and Treatment of Neuroendocrine Tumors with Glucose - Dependent Insulinotropic Polypeptide or Analogues or Antagonists Thereof
EP2986314A4 (en) 2013-03-15 2016-04-13 Univ Indiana Res & Tech Corp PRODRUGS WITH EXTENDED EFFECT
EP3189072B1 (en) * 2014-09-05 2018-07-18 University of Copenhagen Gip peptide analogues
TWI705973B (zh) * 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Ｇｉｐ促效劑化合物及方法
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US10774127B2 (en) * 2016-10-12 2020-09-15 University Of Copenhagen Peptide dual agonists of GIPR and GLP2R
EP3569248B1 (en) 2016-12-26 2023-12-06 Kao Corporation Gip inhibitors for improving cognitive function
EP3560514A4 (en) 2016-12-26 2020-12-23 Kao Corporation Hypothermic drugs
WO2018124011A1 (ja) 2016-12-26 2018-07-05 花王株式会社 運動調節機能向上剤
BR112019025195A8 (pt) 2017-05-31 2020-07-07 Univ Copenhagen análogos do peptídeo gip de ação prolongada

Similar Documents

Publication Publication Date Title
JP2020521784A5 (enExample)
JP7605747B2 (ja) 修飾されたｇｉｐペプチド類似体
JP7658877B2 (ja) インクレチン類似体およびその使用
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
JP5635529B2 (ja) グルカゴン類似体
DK2320923T3 (en) Truncated analogues of glucose-dependent insulinotropic polypeptide
JP2011524420A5 (enExample)
KR20150131213A (ko) 인슐린-인크레틴 접합체들
JP2014141500A (ja) グルカゴン／ｇｌｐ−１受容体コアゴニスト
HUE028072T2 (en) GIP-based agonists for the treatment of metabolic disease and obesity
KR20120123443A (ko) 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
JP2014051501A (ja) Ｎ末端において修飾されたグルコース依存性インスリン分泌刺激ポリペプチド（ｇｉｐ）のアナログ
JP2013510829A (ja) 長時間作用型ｙ２受容体アゴニスト
JP2007001987A5 (enExample)
JP2013505221A (ja) 長時間作用性ｙ２受容体アゴニスト
JP2016512213A5 (enExample)
CN110691788B (zh) 长效gip肽类似物
JPWO2020115048A5 (enExample)
RU2752787C1 (ru) Пептидный аналог ацилированного оксинтомодулина
JP2007536214A (ja) Ｇｌｐ−１類似体
JPWO2021110845A5 (enExample)
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
CA3230220A1 (en) Gip receptor agonist and use thereof
RU2025116817A (ru) Новый тройной агонист рецепторов GLP-1/GIP/глюкагонового рецептора и содержащая его фармацевтическая композиция для предупреждения или лечения ожирения